# DESCRIPTION

## FIELD

- introduce monoclonal antibodies for mesothelin

## BACKGROUND

- motivate mesothelin as therapeutic target
- summarize mesothelin expression in cancers
- describe existing anti-mesothelin monoclonal antibodies
- discuss limitations of existing antibodies
- introduce importance of CDC
- describe CDC mechanism
- highlight need for new anti-mesothelin antibodies

## SUMMARY

- introduce SD1 and SD2 antibodies
- describe SD1 binding and CDC activity
- describe SD2 specificity
- provide monoclonal antibodies with CDRs of SD1 or SD2
- describe compositions and nucleic acid molecules
- introduce immunoconjugates and fusion proteins
- outline uses of antibodies and compositions

## DETAILED DESCRIPTION

### I. Abbreviations

- define abbreviations

### II. Terms and Methods

- define technical terms
- provide explanations of specific terms
- define antibody
- describe immunoglobulin molecules
- explain variable regions
- describe CDRs
- define specificity determining residues
- explain VH and VL regions
- define monoclonal antibody
- describe production of monoclonal antibodies
- define chimeric antibody
- explain human antibody
- define humanized immunoglobulin
- describe construction of humanized immunoglobulins
- define binding affinity
- explain measurement of binding affinity
- define breast cancer
- describe triple negative breast cancer
- define chemotherapeutic agent
- explain use of chemotherapeutic agents
- define cholangiocarcinoma
- explain conservative variant
- provide examples of conservative substitutions
- define complementarity determining region
- explain contacting
- define cytotoxicity
- explain degenerate variant
- define diagnostic
- explain sensitivity and specificity
- define effector molecule
- explain therapeutic agents
- describe diagnostic agents
- define epitope
- explain framework region
- define host cells
- explain hybridoma
- define immune response
- define immunoconjugate
- define label
- describe types of labels
- define linker
- describe types of linkers
- define lung cancer
- define mammal
- define mesothelin
- describe mesothelin protein
- define mesothelioma
- define MORAb-009
- define neoplasia
- describe types of neoplasia
- define operably linked
- define ovarian cancer
- define pancreatic cancer
- define pharmaceutical agent
- describe pharmaceutically acceptable carriers
- define preventing, treating or ameliorating a disease
- define prostate cancer
- define purified
- define recombinant
- define recombinant toxins
- define sample
- define sequence identity
- describe methods of alignment
- define squamous cell carcinoma
- define SS1P
- define stomach cancer
- define subject
- define synthetic
- define therapeutically effective amount
- define toxin
- define vector
- describe general terms
- describe singular terms
- describe base sizes and molecular weights
- describe incorporated references
- describe controlling specification
- describe illustrative examples

### III. Introduction

- introduce monoclonal antibodies against mesothelin
- describe limitations of current antibodies
- introduce SD1 and SD2 antibodies

### IV. Mesothelin-Specific Monoclonal Antibodies

- introduce SD1 and SD2 antibodies
- describe epitope recognition of SD1
- describe CDC and ADCC activity of SD1-hFc
- describe tumor growth inhibition of SD1-hFc
- provide nucleotide and amino acid sequences of SD1 and SD2
- describe isolated monoclonal antibodies that bind mesothelin
- describe VH domain of antibody
- describe binding affinity of monoclonal antibodies
- describe labeling of monoclonal antibodies
- introduce immunoconjugates and fusion proteins
- describe compositions and nucleic acid molecules

### V. Antibodies and Antibody Fragments

- describe isotype of monoclonal antibodies
- introduce antibody fragments
- describe Fab, Fab', and F(ab')2 fragments
- describe Fv and single-chain antibody fragments
- describe VH single-domain antibody
- describe methods of making antibody fragments
- describe conservative variants of antibodies
- provide examples of conservative amino acid substitutions

### VI. Immunoconjugates and Fusion Proteins

- define therapeutic agents
- describe types of therapeutic agents
- explain choice of therapeutic agent
- describe construction of clones with functionally equivalent nucleic acids
- describe linking effector molecules to antibodies
- explain covalent and noncovalent attachment means
- describe procedure for attaching effector molecules
- explain derivatization of antibodies
- describe linkers and their functions
- explain cleavable linkages
- describe enzymatic activity and conditions for cleavage
- summarize methods for attaching agents to antibodies
- describe derivatization of antibodies or antibody fragments
- explain fusion of antibodies to heterologous proteins
- describe functional linking of antibodies to other molecular entities
- explain cross-linking of antibodies
- describe suitable crosslinkers
- explain labeling of antibodies with detectable moieties
- describe useful detection agents
- explain bioluminescent markers
- describe enzymatic labels
- explain indirect measurement of avidin or streptavidin binding
- describe labeling with magnetic agents
- explain labeling with lanthanides and manganese
- describe labeling with paramagnetic particles
- explain labeling with predetermined polypeptide epitopes
- describe labeling with radiolabeled amino acids
- explain derivatization with chemical groups
- describe use of toxins to produce immunotoxins

### VII. Compositions and Methods of Use

- provide compositions with disclosed antibodies
- formulate antibodies for administration
- describe pharmaceutical compositions
- list various aqueous carriers
- describe sterilization techniques
- discuss concentration of antibody in formulations
- provide typical pharmaceutical composition for intravenous administration
- describe lyophilized form of antibodies
- discuss rehydration of lyophilized antibodies
- describe infusion of antibody solution
- provide dosage of antibody administration
- discuss controlled release parenteral formulations
- describe microspheres, microparticles, microcapsules, nanocapsules, nanospheres, and nanoparticles
- discuss administration routes for particles
- describe polymers for ion-controlled release
- discuss block copolymer, polaxamer 407
- describe hydroxyapatite as a microcarrier
- discuss liposomes for controlled release and drug targeting
- list additional systems for controlled delivery of therapeutic proteins
- provide therapeutic methods
- administer antibodies to slow or inhibit tumor growth
- inhibit metastasis of tumor cells
- discuss suitable subjects for treatment
- provide method of treating cancer
- inhibit tumor growth or metastasis
- discuss therapeutically effective amount of antibody
- administer antibodies with other anti-cancer agents
- list exemplary anti-cancer agents
- discuss alkylating agents
- discuss antimetabolites
- discuss natural products
- discuss miscellaneous agents
- discuss hormones and antagonists
- list commonly used chemotherapy drugs
- discuss immunomodulators
- provide methods for diagnosis and detection
- detect expression of mesothelin in vitro or in vivo
- discuss biological samples
- detect cancer in a subject
- confirm diagnosis of cancer
- discuss directly labeled antibodies
- discuss secondary antibodies
- discuss control samples
- provide kits for detecting mesothelin
- discuss instructional materials
- discuss immunoassays
- discuss engineered cytotoxic T lymphocytes (CTLs)
- discuss chimeric antigen receptors (CARs)
- discuss bispecific antibodies

## EXAMPLES

### Example 1

- describe cell culture
- describe screening an engineered human antibody domain library
- describe production of a SD1-human Fc fusion protein
- describe immunoprecipitation and Western blot analysis
- describe ELISA
- describe flow cytometry
- describe ADCC and CDC
- describe xenograft anti-tumor testing in mice
- describe production of a recombinant immunotoxin
- describe cell proliferation inhibition assay
- describe cell culture conditions
- describe phage library construction
- describe phage panning
- describe protein purification
- describe Western blot analysis

### Example 2

- describe discovery and production of the SD1 human antibody
- describe epitope mapping
- describe phage panning
- describe peptide synthesis
- describe phage titer analysis
- describe clone selection
- describe SD1-hFc production
- describe Western blot analysis
- describe pull-down assays
- describe ELISA
- describe competition ELISA
- describe binding kinetics
- describe flow cytometry
- describe cell surface binding
- describe CDC and ADCC
- describe C1q binding
- describe ADCC activity
- describe CDC activity
- describe anti-tumor activity in mice
- describe tumor growth inhibition
- describe CDC in mice
- describe ADCC in mice
- describe mouse NK cell purification
- describe conclusion

## DISCUSSION

- introduce SD1 antibody
- describe in vitro CDC activity
- describe in vivo tumor growth inhibition
- motivate conformational epitope binding
- discuss limitations of existing antibodies
- describe SD1-hFc protein production
- summarize anti-tumor activity
- discuss human single-domain VHs

## Example 3

### Mesothelin-Specific Monoclonal Antibodies for Detecting Cancer in a Subject or Confirming the Diagnosis of Cancer in a Subject

- describe ELISA method
- detect soluble mesothelin in blood sample
- confirm diagnosis of cancer

### Example 4

- describe treatment of mesothelin-positive cancers
- administer immunoconjugate with Pseudomonas exotoxin
- administer SD1 or SD1-hFc fusion protein
- describe dosing and administration regimens
- evaluate cancer progression and clinical signs

